Tuesday - May 13, 2025
SALT LAKE CITY, UT / ACCESSWIRE / August 13, 2024 / KindlyMD, Inc. ("KindlyMD" or the "Company") (NASDAQ:KDLY), a patient-first healthcare and healthcare data company uniquely integrating traditional primary care and pain management strategies with integrated behavioral and alternative therapies, is pleased to announce that management is scheduled to participate in the following August 2024 conferences.
Sidoti Micro-Cap Virtual Conference
Presentation Date and Time: Wednesday, August 14th at 11:30 a.m. ET
Webcast: https://sidoti.zoom.us/webinar/register/WN_VkaugCtaSp-QPy2xNOfuqA
Summer 2024 Investor Summit Virtual Conference
Presentation Date and Time: Tuesday, August 20th at 12:30 p.m. ET
Webcast: https://investors.kindlymd.com/events-presentations
To schedule a one-on-one meeting with the Company's management team, please contact your representative at Sidoti, Investor Summit Group, or email KCSA Strategic Communications at KindlyMD@KCSA.com.
About KindlyMD
KindlyMD™ is a patient-first healthcare and healthcare data company uniquely integrating traditional primary care and pain management strategies with integrated behavioral and alternative therapies to offer patients comprehensive care and reduce the addiction and dependency of opioid use in the U.S. KindlyMD currently operates four centers including the largest alternative pain treatment center in Utah. With a focus on holistic pain management through its specialty outpatient clinical services, including, where appropriate, the recommendation of medical cannabis by KindlyMD healthcare providers, KindlyMD is providing better patient health outcomes.
For more information, please visit www.kindlymd.com.
Investor Relations Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
(212) 896-1254
KindlyMD@KCSA.com
Last Trade: | US$13.57 |
Daily Change: | 9.67 247.95 |
Daily Volume: | 65,070,314 |
Market Cap: | US$81.150M |
January 22, 2025 November 13, 2024 October 29, 2024 October 08, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load